Market Overview

UPDATE: Credit Suisse Initiates Endocyte at Outperform Ahead of Catalysts

Related ECYT
Why Endocyte Could Be Positioned For A Surge
Benzinga's Top Downgrades
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)

Credit Suisse initiated coverage on Endocyte, Inc. (NASDAQ: ECYT) with a Outperform rating and a $16.00 price target.

Credit Suisse noted, "We anticipate significant stock appreciation ahead of key events in early 2014, including a potential EU approval, pivotal Phase III data in ovarian cancer, and robust Phase II data in lung cancer. Limited catalysts in 2013 and the potential for EU regulatory delays could limit near-term upside. However, with sufficient cash, a deep-pocket partner (Merck), and multiple significant catalysts in early 2014, we believe the risk/reward is favorable."

Endocyte closed at $9.32 on Monday.

Latest Ratings for ECYT

Sep 2014Brean CapitalDowngradesBuyHold
Sep 2014CitigroupMaintainsNeutral
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for ECYT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (ECYT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content